Structure-activity relationship between PKC412 analogs and SYK... | Download Scientific Diagram
Frontiers | Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder | PNAS
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function | Haematologica
Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells
PKC412 - LKT Labs
Primary clinical resistance to PKC412 therapy in an AML patient with... | Download Scientific Diagram
Midostaurin: a magic bullet that blocks mast cell expansion and activation - Annals of Oncology
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development - Kiyoi - 2020 - Cancer Science - Wiley Online Library
Midostaurin: an emerging treatment for acute myeloid leukemia patients | JBM
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain - ScienceDirect
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain - ScienceDirect
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology
CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML - Waldeck - 2020 - Molecular Oncology - Wiley Online Library
Isobolograms of simultaneous exposure to PKC412 and conventional... | Download Scientific Diagram
Evolving Therapeutic Options for Acute Myeloid Leukemia
Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells | PLOS ONE
FDA grants Breakthrough Therapy status to PKC412
A) Comparison of rate of proliferation of MOLM13-S, MOLM13-R-PKC412... | Download Scientific Diagram
Cancers | Free Full-Text | Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia | HTML
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations | Oncogene
Jan 04 nwsltr working - The Life Raft Group
![PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b825a5d927ce38433166e20b17c67b5fa1f2f0b6/6-Table6-1.png "PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar")
PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar
Dose–response curves of PKC412 for MOLM13, MOLM14, MV4-11, KOPB-26,... | Download Scientific Diagram
Inhibition of FLT3-ITD signaling by AG1295 or PKC412 leads to induction... | Download Scientific Diagram
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder | PNAS
